Loading...
Please wait, while we are loading the content...
Similar Documents
Should minimal residual disease negativity not be the end point of myeloma therapy?
| Content Provider | Semantic Scholar |
|---|---|
| Author | Sonneveld, P. |
| Copyright Year | 2017 |
| Abstract | Publisher's Note: This article has a companion Point by Anderson. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations. |
| Starting Page | 522 |
| Ending Page | 525 |
| Page Count | 4 |
| File Format | PDF HTM / HTML |
| DOI | 10.1182/bloodadvances.2017000109 |
| PubMed reference number | 29296971 |
| Journal | Medline |
| Volume Number | 1 |
| Issue Number | 8 |
| Alternate Webpage(s) | http://www.bloodadvances.org/content/bloodoa/1/8/522.full.pdf?sso-checked=true |
| Alternate Webpage(s) | https://doi.org/10.1182/bloodadvances.2017000109 |
| Journal | Blood advances |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |